FGF-21 research in Canada investigates the metabolic regulatory properties of fibroblast growth factor 21, a member of the FGF superfamily that acts as an endocrine hormone. FGF-21 is primarily produced by the liver and signals through FGFR1c/β-Klotho receptor complexes on adipose tissue, muscle, and brain. Canadian metabolic disease researchers study FGF-21 for its effects on adiponectin secretion, insulin sensitivity, energy expenditure, and fatty acid oxidation — positioning it as a key regulator of metabolic homeostasis.
Adiponectin and Insulin Sensitivity Research
FGF-21 stimulates adiponectin secretion from white and brown adipose tissue through FGFR1c/β-Klotho receptor activation. Adiponectin then enhances hepatic insulin sensitivity and muscle glucose uptake. Canadian metabolic researchers study this FGF-21-adiponectin axis to understand how liver-derived hormones communicate with adipose tissue to regulate whole-body insulin sensitivity.
Brown Adipose Tissue and Thermogenesis Research
FGF-21 activates brown adipose tissue (BAT) and promotes browning of white adipose tissue through FGFR1c/β-Klotho in adipocytes, upregulating UCP1 expression and thermogenesis. Canadian obesity researchers study FGF-21 to understand how endocrine FGF signalling drives adaptive thermogenesis and whether this can be harnessed for metabolic disease research.
Sourcing FGF-21 in Canada
Research-grade FGF-21 is available in Canada from EhBuddy Peptides. Lab-tested for purity. For laboratory research use only.
FGF-21 is a rapidly emerging metabolic hormone in Canadian research, sitting at the intersection of liver-adipose tissue crosstalk, insulin sensitization, and adaptive thermogenesis biology.
